HK1201175A1 - Antigen presenting cancer vaccine with gamma interferon - Google Patents

Antigen presenting cancer vaccine with gamma interferon Download PDF

Info

Publication number
HK1201175A1
HK1201175A1 HK15101635.2A HK15101635A HK1201175A1 HK 1201175 A1 HK1201175 A1 HK 1201175A1 HK 15101635 A HK15101635 A HK 15101635A HK 1201175 A1 HK1201175 A1 HK 1201175A1
Authority
HK
Hong Kong
Prior art keywords
cells
gamma
antigen presenting
cancer vaccine
gamma interferon
Prior art date
Application number
HK15101635.2A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew CORNFORTH
Robert DILLMAN
Original Assignee
Neostem Oncology, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neostem Oncology, Llc filed Critical Neostem Oncology, Llc
Publication of HK1201175A1 publication Critical patent/HK1201175A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15101635.2A 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon HK1201175A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US61/549,681 2011-10-20
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2012/061294 WO2013059778A2 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Publications (1)

Publication Number Publication Date
HK1201175A1 true HK1201175A1 (en) 2015-08-28

Family

ID=48141460

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15101635.2A HK1201175A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon
HK15101637.0A HK1201176A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15101637.0A HK1201176A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine

Country Status (11)

Country Link
US (2) US20140308316A1 (enExample)
EP (2) EP2768519A4 (enExample)
JP (2) JP2014530627A (enExample)
KR (2) KR20150016200A (enExample)
CN (5) CN105861437A (enExample)
AU (2) AU2012325764A1 (enExample)
CA (2) CA2852960A1 (enExample)
HK (2) HK1201175A1 (enExample)
IL (2) IL232172A0 (enExample)
SG (4) SG10201508535RA (enExample)
WO (2) WO2013059778A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
WO2013059778A2 (en) * 2011-10-20 2013-04-25 California Stem Cell, Inc. Antigen presenting cancer vaccine with gamma interferon
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
CN107109365A (zh) * 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
CA3023265A1 (en) * 2016-05-05 2017-11-09 Nantomics, Llc Checkpoint failure and methods therefor
EP3582793A4 (en) * 2017-02-17 2020-12-16 Aivita Biomedical, Inc. METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
PT1224264E (pt) 1999-10-15 2010-03-15 Baylor Res Inst Modificação de células imunogénicas
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
JP2005515192A (ja) * 2001-11-29 2005-05-26 ダンドリット バイオテック アクティーゼルスカブ ヒト又は動物において免疫応答を誘導するための医薬組成物
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
JP5281399B2 (ja) * 2005-07-29 2013-09-04 プロビデンス ヘルス システム 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法
EP1951318B1 (en) * 2005-11-07 2012-10-17 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
WO2008005859A2 (en) * 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
WO2013059778A2 (en) 2011-10-20 2013-04-25 California Stem Cell, Inc. Antigen presenting cancer vaccine with gamma interferon

Also Published As

Publication number Publication date
KR20150004791A (ko) 2015-01-13
SG10201602424RA (en) 2016-05-30
WO2013059778A3 (en) 2013-07-04
HK1201176A1 (en) 2015-08-28
NZ623915A (en) 2016-02-26
CN105999249A (zh) 2016-10-12
CN105861437A (zh) 2016-08-17
JP2014533938A (ja) 2014-12-18
EP2768519A4 (en) 2015-07-01
SG11201401632WA (en) 2014-05-29
EP2768534A4 (en) 2015-04-01
US9555058B2 (en) 2017-01-31
AU2012325764A1 (en) 2014-04-24
AU2012325758A1 (en) 2014-04-24
WO2013059778A2 (en) 2013-04-25
WO2013059784A1 (en) 2013-04-25
SG10201508535RA (en) 2015-11-27
IL232173A0 (en) 2014-06-30
CA2852960A1 (en) 2013-04-25
CN103917246A (zh) 2014-07-09
EP2768519A2 (en) 2014-08-27
KR20150016200A (ko) 2015-02-11
US20140314814A1 (en) 2014-10-23
CN105288602A (zh) 2016-02-03
CA2852967A1 (en) 2013-04-25
CN103957925A (zh) 2014-07-30
US20140308316A1 (en) 2014-10-16
SG11201401631VA (en) 2014-05-29
NZ623917A (en) 2016-09-30
IL232172A0 (en) 2014-06-30
EP2768534A1 (en) 2014-08-27
JP2014530627A (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
WO2013059778A3 (en) Antigen presenting cancer vaccine with gamma interferon
HK1243631A1 (zh) 用於提高过继细胞免疫疗法效力的组合物和方法
EP4219690A3 (en) Methods of cancer treatment using activated t cells
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
AU2018254566A1 (en) Oncolytic virotherapy and immunotherapy
WO2007126805A3 (en) Cancer immunotherapy compositions and methods of use
WO2011143656A3 (en) Compositions and methods of identifying tumor specific neoantigens
TN2015000050A1 (en) Methods of treating a tauopathy
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
EP3194577A4 (en) Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
IL266131A (en) Compositions for reprogramming cells into dendritic cells or antigen-presenting cells, methods and uses thereof
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2013084071A3 (en) Clostridium difficile toxin-based vaccine
EP2831101A4 (en) LOADED NUTRIENT FRAGMENTS, PROTEINS AND METHOD
WO2016077789A8 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
WO2011156690A3 (en) Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
MX2014006187A (es) Composiciones y metodos para el analisis de cancer de prostata.
EP3516057A4 (en) METHOD FOR GENOTYPING HUMAN LEUKOCYTE ANTIGEN AND DETERMINING HAPLOTYP DIVERSITY IN A POPULATION
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
MX2016017136A (es) Composiciones y metodos para detectar pegivirus 2 de humano (hpgv-2).
HK1202432A1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
WO2009114816A3 (en) Therapeutic cancer antigens